Sichuan Huiyu Pharmaceutical Co.,Ltd.

About Sichuan Huiyu Pharmaceutical Co.,Ltd.

Huiyu pharm, founded in 2010, is a comprehensive pharmaceutical enterprise driven by research and development, mainly engaged in the research and development, production, and sales of anti-tumor injection.Also,it's dedicated to R&D and manufacturing of API products, with facilities approved by EU EDQM and China NMPA.Huiyu's products range from oncology,anti-infective to IDA, etc.

Certifications
  • CN
  • 2015
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
Contact info
Meet us at

CPHI & PMEC China 2024

Shanghai New International Expo Center
19 - 21 June 2024

CPHI South East Asia 2024

Queen Sirikit National Convention Center, Bangkok, Thailand
10 Jul 2024 - 12 Jul 2024

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Sichuan Huiyu Pharmaceutical Co.,Ltd. (5)

  • Azacitidine Seacross 25mg/ml Powder for suspension for injection

    Product Azacitidine Seacross 25mg/ml Powder for suspension for injection

    Therapeutic indications:Azacitidine Seacross is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

    •intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System ...
  • Zoledronic Acid Seacross 5mg/100ml solution for infusion

    Product Zoledronic Acid Seacross 5mg/100ml solution for infusion

    Therapeutic indications:  
    Treatment of osteoporosis:•in post-menopausal women•in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: •in post-menopausal wo...
  • Docetaxel 20 mg/ml Concentrate for solution for infusion

    Product Docetaxel 20 mg/ml Concentrate for solution for infusion

    Therapeutic indications:Breast cancer, sarcoma, small-cell carcinoma of the lung, Hodgkin disease or non-Hodgkin lymphoma, acute leukaemia, cancer of the thyroid, bladder, ovaries, Paediatric tumours, such as neuroblastoma. Doxorubicin is frequently used in combination chemotherapy regimens with other...
  • API: Carfilzomib/Bortezomib/Thiotepa/Ferric Carboxymaltose/Goserelin acetate/Ixazomib citrate

    Product API: Carfilzomib/Bortezomib/Thiotepa/Ferric Carboxymaltose/Goserelin acetate/Ixazomib citrate

    ——1. Carfilzomib: commercial API, DMF available, W.C. to be available in April 2024 2024)——Bortezomib: commercial API, DMF available, W.C. to be available in April 2024
    ——2. Thiotepa: 
    Commercial API, DMF available, W.C. to be available in April 2024
    ——3. Ferric carboxymaltose: ...
  • Paclitaxel 6 mg/ml concentrate for solution for infusion

    Product Paclitaxel 6 mg/ml concentrate for solution for infusion

    Paclitaxel Injection is used to treat:

    Ovarian cancer:

    • as first therapy (after initial surgery in combination with the platinum-containing medicine cisplatin).

    • after standard platinum-containing medicines have been tried but did not work.
    ...